Revolution Medicines
RVMD
386 hedge funds and large institutions have $15.9B invested in Revolution Medicines in 2025 Q4 according to their latest regulatory filings, with 107 funds opening new positions, 135 increasing their positions, 101 reducing their positions, and 39 closing their positions.
546% more call options, than puts
Call options by funds: $247M | Put options by funds: $38.2M
174% more first-time investments, than exits
New positions opened: 107 | Existing positions closed: 39
77% more capital invested
Capital invested by funds: $8.96B → $15.9B (+$6.91B)
38% more funds holding in top 10
Funds holding in top 10: 24 → 33 (+9)
34% more repeat investments, than reductions
Existing positions increased: 135 | Existing positions reduced: 101
20% more funds holding
Funds holding: 323 → 386 (+63)
0.46% more ownership
Funds ownership: 102.63% → 103.09% (+0.46%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$142M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$131M |
| 3 |
Goldman Sachs
New York
|
+$115M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$101M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$95.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$185M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$169M |
| 3 |
JP Morgan Chase
New York
|
-$136M |
| 4 |
ACM
AH Capital Management
Menlo Park,
California
|
-$120M |
| 5 |
Holocene Advisors
New York
|
-$100M |
RVMD Hedge Fund Activity: Q4 2025 in Review
386 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q4 2025, worth a combined $15.9B — up 77% from $8.96B a quarter earlier.
Buyers outnumbered sellers: 107 funds opened new RVMD positions and 39 closed out — a net gain of 68 holders — while 135 added to existing stakes and 101 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $142M. The largest seller was Wellington Management Group, cutting an estimated $185M.
- 386 institutional investors held Revolution Medicines (RVMD) as of Q4 2025, up from 323 in Q3 2025.
- Funds reported $15.9B of Revolution Medicines stock for Q4 2025, up 77% quarter-over-quarter.
- 107 funds opened new Revolution Medicines positions in Q4 2025 and 39 closed out, a net change of +68 holders.
- The largest Revolution Medicines buyer in Q4 2025 was Avoro Capital Advisors, an estimated $142M added.
- The largest Revolution Medicines seller in Q4 2025 was Wellington Management Group, an estimated $185M sold.
Based on aggregated 13F filings for Q4 2025.